Abstract
Metastatic breast cancer is a leading cause of cancer-related deaths
in women worldwide. Patients with triple negative breast cancer
(TNBCs), a highly aggressive tumor subtype, have a particularly poor
prognosis. Multiple reports demonstrate that altered content of the
multicopy mitochondrial genome (mtDNA) in primary breast tumors
correlates with poor prognosis. We earlier reported that mtDNA copy
number reduction in breast cancer cell lines induces an
epithelial-mesenchymal transition associated with metastasis.
However, it is unknown whether the breast tumor subtypes (TNBC,
Luminal and HER2+) differ in the nature and amount of mitochondrial
defects and if mitochondrial defects can be used as a marker to
identify tumors at risk for metastasis. By analyzing human primary
tumors, cell lines and the TCGA dataset, we demonstrate a high degree
of variability in mitochondrial defects among the tumor subtypes and
TNBCs, in particular, exhibit higher frequency of mitochondrial
defects, including reduced mtDNA content, mtDNA sequence imbalance
(mtRNR1:ND4), impaired mitochondrial respiration and metabolic switch
to glycolysis which is associated with tumorigenicity. We identified
that genes involved in maintenance of mitochondrial structural and
functional integrity are differentially expressed in TNBCs compared
to non-TNBC tumors. Furthermore, we identified a subset of TNBC
tumors that contain lower expression of epithelial splicing
regulatory protein (ESRP)-1, typical of metastasizing cells. The
overall impact of our findings reported here is that mitochondrial
heterogeneity among TNBCs can be used to identify TNBC patients at
risk of metastasis and the altered metabolism and metabolic genes can
be targeted to improve chemotherapeutic response.
(Molecular Basis of Disease, Volume 1864, Issue 4(A), Pages 1060-1071
doi:10.1016/j.bbadis.2018.01.002, 2018)